Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

which was acquired by GSK when it took over Tesaro in a $5.1 billion deal agreed in 2019, along with PARP inhibitor Zejula (niraparib). There are a number of other TIM-3 targeting drugs coming ...

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Q4 2024 Earnings Call Transcript February 13, 2025 Blueprint Medicines Corporation misses on earnings expectations. Reported ...

The company says new IL-5 inhibitor depemokimab (formerly ... often juggling multiple therapies, he added. GSK is also running a third phase 3 trial of depemokimab, called NIMBLE, that is ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and ...

Last year, GSK had 13 positive Phase 3 readouts a record achievement for ... a very promising and highly selective KIT tyrosine kinase inhibitor designed to treat gastrointestinal stromal tumors.

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab ... with an average gain of +24.3% per year. So be sure to give ...

Reports Q4 revenue $7M, consensus $4.31M. The net loss for the three months ended December 31, 2024, was $130.3M compared to the net loss of ...

Phase 3 trial results GSK5764227 (GSK) Antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload Treatment of relapsed ...